Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q1 2026
Kiniksa Pharmaceuticals International (KNSA) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 28, 2026
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $214M for the first quarter 2026 (Q1 2026), +56% from a year earlier and +6% from the quarter before. Operating margin was 13.7%, net earnings $22.6M (10.5% of revenue).
Kiniksa Pharmaceuticals International, Q1 2026: revenue $214M (+56% year over year), operating margin 13.7%, net earnings $22.6M, operating cash flow $50.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $214M | +6% | +56% |
| Operating profit | $29.3M | +48% | +121% |
| Net earnings | $22.6M | +59% | +165% |
| Operating cash flow | $50.2M | -7% | +125% |
| Free cash flow | $50.0M | -6% | +125% |
What changed
Revenue was $214.3M in Q1 2026, up 56% year over year and up 6% from the previous quarter.
Operating profit was $29.3M, a 13.7% margin (up 4.0 points year over year). Of the extra revenue versus Q1 2025, 21% reached operating profit, above the 10% margin then. Total costs grew 49% against revenue growth of 56%. The fastest-growing cost line was Other operating costs (+73%). Net earnings were $22.6M, up 165% year over year. The effective tax rate was 30.9%.
Operating cash flow was $50.2M (up 125% year over year), 222% of net earnings. Non-cash charges added back $468K of depreciation and amortization and $10.1M of share-based compensation. Working capital and other items added $17.1M. Capital expenditures of $161K left free cash flow of $50.0M.
Questions
What was Kiniksa Pharmaceuticals International's revenue in the first quarter 2026?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $214M for the first quarter 2026 (Q1 2026), +56% from a year earlier and +6% from the quarter before.
Was Kiniksa Pharmaceuticals International profitable in the first quarter 2026?
Operating profit was $29.3M (13.7% of revenue) and net earnings $22.6M.
Source: Kiniksa Pharmaceuticals International 10-Q on SEC EDGAR.